Skip to main content


Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Fig. 5 | Genome Medicine

Fig. 5

From: Associating somatic mutations to clinical outcomes: a pan-cancer study of survival time

Fig. 5

Mutation rate, purity, ploidy, and proportion of clonal mutation summary: mutation load per megabase within the whole exome and ASCAT-derived purity and ploidy across 14 cancer types ordered by a median mutation rate. Violin plots in magenta contain nested boxplots with the median represented by the black box. The top panel shows the distribution of the proportion of inferred clonal mutations across all samples for each cancer type. The cancer types are bladder urothelial carcinoma (BLCA), breast invasive carcinoma (BRCA), colon adenocarcinoma (COAD), glioblastoma multiforme (GBM), head/neck squamous cell carcinoma (HNSC), kidney renal clear cell carcinoma (KIRC), lower-grade glioma (LGG), liver hepatocellular carcinoma(LIHC), lung adenocarcinoma (LUAD), lung squamous cell carcinoma (LUSC), ovarian serous cystadenocarcinoma (OV), prostate adenocarcinoma (PRAD), skin cutaneous melanoma (SKCM), and stomach adenocarcinoma (STAD)

Back to article page